Tracks pregnancy and infant outcomes of people taking anifrolumab for lupus
Observes pregnancies in people with lupus who were exposed to anifrolumab.
Plain-language title generated from the registry record
Registry title: The Anifrolumab PRIM Program
Key facts
- Where
- Södertälje, SwedenSee the site
Where in Sweden
- Reseach FacilitySödertälje, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06795893
- Record updated
- 11 September 2026
- Original description
Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM programRead full original descriptionShow less
Pregnancy and Infant Outcomes in Anifrolumab Exposed Pregnancies Using PRegnancy Outcomes Intensive Monitoring (PRIM) Data: The Anifrolumab PRIM Program
Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program
Inclusion: Currently or recently (within 1 year of pregnancy outcome) pregnant; Exposure to at least 1 dose of anifrolumab at any time during pregnancy or in the 16 weeks prior to date of conception.
Exclusion: Pregnancy cases that have been enrolled in the prospective pregnancy registry (D3461R00051), those reported prior to the start of the PRIM program, or those that have been exposed to known teratogens or investigational medications will be excluded from the anifrolumab PRIM study.